Colby Pharmaceutical Company is a privately held company developing non-toxic signal transduction and hypoxia inhibitor drug therapeutics specifically targeting survival pathways in solid tumor cells, immune or immune supressed cells and vas-occlusive conditions. The Company is transitioning to clinical stage drug development and has scheduled its lead drugs for clinical trials in 2010.
The development of these drugs has been financed by grants and private investors. Colby is currently seeking strategic partners and equity investors.
The lead drug, CPC-100, is a first-in-class therapeutic for treatment of both Androgen-Dependent PCa (ADPCa) as well as Androgen Independent PCa (AIDPCa). In animal PCa models CPC-100 is more effective compared to standard of care (SOC) Androgen Depletion Therapy (ADT) drugs, which are only therapeutic for ADPCa patients and are inactive with AIDPCa. CPC-100 is 225 times more effective than SOC ADT drugs in treating experimental mouse prostate tumors, does not have negative pro-estrogenic side effects of SOC ADT drugs and significantly increases survival in animal models.
CPC-100 is being developed as a stand alone drug for a Phase I/IIa clinical trial in recurrent asymptomatic PCa patients who are resistant to surgery or radiation and ADT, for whom there is currently no approved drug treatment. CPC-100 IND-enabling large animal toxicology is now complete.
The Company is strategically affiliated with the University of Wisconsin-Madison's Paul P. Carbone Comprehensive Cancer Center and the Wisconsin Alumni Research Foundation. Colby has assembled a experienced team, including clinical oncologists and pharmaceutical experts to bring these drugs through clinical development.
Most (>70%) therapy-resistant solid cancers are hypoxic and the well- established hypoxic tumor effect has been clinically observed for 25 years. Hypoxia has a major role in Radio-, Chemo-, Immuno-therapy resistant tumors and numerous published reviews show oncologists are aware of the need for drugs in hypoxia and therapy-resistance, simplifying education and marketing.
Colby is establishing global collaborations and has focused on drugs for hypoxia and therapy-resistance. These drugs are stand-alone mono-therapies or combo-therapies with SOC Radiation Therapy (RT) for hypoxic & therapy-resistant tumors.
